MGI PHARMA, INC. Announces Results from Study Involving the Dual Implantation of Gliadel® Wafer and Radioactive Seeds for Treatment of Recurrent Glioblastoma Multiforme

MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (NASDAQ:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that study results published in the February issue of the Journal of Neurosurgery show that treatment of patients who have recurrent glioblastoma multiforme (GBM) with both Gliadel® Wafer and radioactive seeds (iodine-125) at the time of tumor resection, may provide for a better outcome than treatment of patients with surgery and either agent alone.